{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:24Z","timestamp":1792035804583,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Negative affect is a key factor in Alcohol Use Disorder (AUD) associated with craving and relapse risk that is insufficiently treated by approved medications. Cannabidiol (CBD) has shown promising effects on negative affect, indicating its potential for addressing the neurocircuitry underlying negative affect in AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study investigates CBD\u2019s effects on neural response to negative emotional stimuli and subjective alcohol craving in individuals with AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted the first neuroimaging study investigating CBD\u2019s effects on neural responses to negative emotional stimuli and craving in AUD. The study was designed as two armed, 1:1 randomized, double blind, parallel group neuroimaging trial, enrolled\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200928 individuals with AUD. It compared the effects of 800\u00a0mg oral CBD versus matched Placebo (PLC) on blood oxygenated level dependent (BOLD) response in the amygdala during a validated emotion processing task and explored associations with CBD plasma levels and subjective alcohol craving.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CBD versus PLC attenuated bilateral amygdala reactivity to angry and fearful faces (\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FWE<\/jats:sub>\n                      \u2009&lt;.05, small volume corrected), while CBD showed no effect on amygdala activation during the presentation of neutral shape stimuli. Amygdala response to negative emotional stimuli correlated positively with the extent of subjective alcohol craving (\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>Left Amygdala<\/jats:sub>\n                      \u2009=.52,\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=.01;\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>Right Amygdala<\/jats:sub>\n                      \u2009=.52,\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=.01) and negatively with CBD plasma levels (\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>Left Amygdala<\/jats:sub>\n                      \u2009=\u2009-.68,\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=\u20090.002;\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>Right Amygdala<\/jats:sub>\n                      \u2009=\u2009-.65,\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>FDR<\/jats:sub>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, CBD\u2019s effects on amygdala reactivity to negative emotional stimuli in individuals with AUD support CBD\u2019s potential for modulating emotion-processing circuits in AUD and CBD\u2019s treatment potential for craving and relapse driven by negative affective states.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-025-06860-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:24:25Z","timestamp":1756445065000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder \u2013 a randomized controlled trial"],"prefix":"10.1007","volume":"243","author":[{"given":"Marlen","family":"Pfisterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Teetzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joscha","family":"Bae\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Zaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Stenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"5","key":"6860_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00406-020-01115-0","volume":"271","author":"P Bach","year":"2021","unstructured":"Bach P et al (2021) Oxytocin attenuates neural response to emotional faces in social drinkers: an fMRI study. Eur Arch Psychiatry Clin Neurosci 271(5):873\u2013882","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6860_CR2","doi-asserted-by":"publisher","first-page":"618184","DOI":"10.3389\/fphar.2020.618184","volume":"11","author":"A Batalla","year":"2020","unstructured":"Batalla A et al (2020) The impact of cannabidiol on human brain function: a systematic review. Front Pharmacol 11:618184","journal-title":"Front Pharmacol"},{"issue":"3","key":"6860_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3):764\u2013774","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"6860_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","volume":"20","author":"A Bilbao","year":"2022","unstructured":"Bilbao A, Spanagel R (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med 20(1):259","journal-title":"BMC Med"},{"key":"6860_CR5","doi-asserted-by":"publisher","first-page":"7 S","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","volume":"19","author":"MJ Bohn","year":"1995","unstructured":"Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19:7 S","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"6860_CR6","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E et al (2020) Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45(11):1799\u20131806","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"6860_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1176\/ajp.156.1.11","volume":"156","author":"AR Childress","year":"1999","unstructured":"Childress AR et al (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156(1):11\u201318","journal-title":"Am J Psychiatry"},{"issue":"2","key":"6860_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA Crippa","year":"2004","unstructured":"Crippa JA et al (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29(2):417\u2013426","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"6860_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA et al (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25(1):121\u2013130","journal-title":"J Psychopharmacol"},{"issue":"1","key":"6860_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0862-2","volume":"10","author":"C Davies","year":"2020","unstructured":"Davies C et al (2020) A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry 10(1):311","journal-title":"Transl Psychiatry"},{"key":"6860_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.134773","volume":"722","author":"SF Dean","year":"2020","unstructured":"Dean SF et al (2020) Addiction neurocircuitry and negative affect: a role for neuroticism in understanding amygdala connectivity and alcohol use disorder. Neurosci Lett 722:134773","journal-title":"Neurosci Lett"},{"issue":"4","key":"6860_CR12","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.psycom.2022.100074","volume":"2","author":"DK Fliegel","year":"2022","unstructured":"Fliegel DK, Lichenstein SD (2022) Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety. Psychiatry Res Commun 2(4):100074","journal-title":"Psychiatry Res Commun"},{"issue":"33","key":"6860_CR13","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.1523\/JNEUROSCI.1505-16.2016","volume":"36","author":"D Funk","year":"2016","unstructured":"Funk D et al (2016) Role of central amygdala neuronal ensembles in incubation of nicotine craving. J Neurosci 36(33):8612\u20138623","journal-title":"J Neurosci"},{"issue":"4","key":"6860_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1017\/S1461145709990617","volume":"13","author":"P Fusar-Poli","year":"2010","unstructured":"Fusar-Poli P et al (2010) Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13(4):421\u2013432","journal-title":"Int J Neuropsychopharmacol"},{"key":"6860_CR15","doi-asserted-by":"publisher","first-page":"2 S","DOI":"10.1159\/000223610","volume":"19","author":"J Gaab","year":"2009","unstructured":"Gaab J (2009) PASA \u2013 primary appraisal secondary appraisal. Verhaltenstherapie 19:2 S","journal-title":"Verhaltenstherapie"},{"key":"6860_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.neubiorev.2016.04.020","volume":"68","author":"I Garc\u00eda-Garc\u00eda","year":"2016","unstructured":"Garc\u00eda-Garc\u00eda I et al (2016) Neural processing of negative emotional stimuli and the influence of age, sex and task-related characteristics. Neurosci Biobehav Rev 68:773\u2013793","journal-title":"Neurosci Biobehav Rev"},{"issue":"11","key":"6860_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/biom10111575","volume":"10","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez MS et al (2020) Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules 10(11):1575","journal-title":"Biomolecules"},{"issue":"6","key":"6860_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.21121207","volume":"180","author":"KA Garrison","year":"2023","unstructured":"Garrison KA et al (2023) Transdiagnostic connectome-based prediction of craving. Am J Psychiatry 180(6):445\u2013453","journal-title":"Am J Psychiatry"},{"key":"6860_CR19","doi-asserted-by":"crossref","unstructured":"Gom RC et al (2025) Phytocannabinoids restore seizure-induced alterations in emotional behaviour in male rats. Neuropsychopharmacology 50(5):751\u2013761","DOI":"10.1038\/s41386-024-02005-y"},{"issue":"5","key":"6860_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/acer.13046","volume":"40","author":"JL Gowin","year":"2016","unstructured":"Gowin JL et al (2016) The effect of varenicline on the neural processing of fearful faces and the subjective effects of alcohol in heavy drinkers. Alcohol Clin Exp Res 40(5):979\u2013987","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"6860_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/nimg.2002.1179","volume":"17","author":"AR Hariri","year":"2002","unstructured":"Hariri AR et al (2002) The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 17(1):317\u2013323","journal-title":"Neuroimage"},{"key":"6860_CR22","unstructured":"Hautzinger M, Keller F K\u00fchner C (2006) Beck depressions-inventar: BDI II. Revision. Revision ed. 2006, Frankfurt am Main: harcourt test services"},{"key":"6860_CR23","doi-asserted-by":"crossref","unstructured":"Heilig M et al (2024) Novel medications for problematic alcohol use. J Clin Investig 134(11):1\u201312","DOI":"10.1172\/JCI172889"},{"issue":"5","key":"6860_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41386-020-0600-8","volume":"45","author":"L Hogarth","year":"2020","unstructured":"Hogarth L (2020) Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology 45(5):720\u2013735","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"6860_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176(11):911\u2013922","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6860_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42238-024-00224-0","volume":"6","author":"T Hurzeler","year":"2024","unstructured":"Hurzeler T et al (2024) Neuroimaging studies of cannabidiol and potential neurobiological mechanisms relevant for alcohol use disorders: a systematic review. J Cannabis Res 6(1):15","journal-title":"J Cannabis Res"},{"issue":"1","key":"6860_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2(1):139\u2013154","journal-title":"Cannabis Cannabinoid Res"},{"issue":"23","key":"6860_CR28","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1523\/JNEUROSCI.21-23-09506.2001","volume":"21","author":"I Katona","year":"2001","unstructured":"Katona I et al (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21(23):9506\u20139518","journal-title":"J Neurosci"},{"issue":"49","key":"6860_CR29","doi-asserted-by":"publisher","first-page":"11489","DOI":"10.1523\/JNEUROSCI.3984-05.2005","volume":"25","author":"P Kirsch","year":"2005","unstructured":"Kirsch P et al (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25(49):11489\u201311493","journal-title":"J Neurosci"},{"issue":"3","key":"6860_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14728214.2024.2342951","volume":"29","author":"S K\u00f6hne","year":"2024","unstructured":"K\u00f6hne S et al (2024) Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. Expert Opin Emerg Drugs 29(3):219\u2013232","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"6860_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35(1):217\u2013238","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"6860_CR32","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB et al (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172(20):4790\u20134805","journal-title":"Br J Pharmacol"},{"issue":"3","key":"6860_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/jocmr4090","volume":"12","author":"C Larsen","year":"2020","unstructured":"Larsen C, Shahinas J (2020) Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 12(3):129\u2013141","journal-title":"J Clin Med Res"},{"issue":"5","key":"6860_CR34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/npp.2014.320","volume":"40","author":"X Li","year":"2015","unstructured":"Li X et al (2015) The central amygdala nucleus is critical for incubation of methamphetamine craving. Neuropsychopharmacology 40(5):1297\u20131306","journal-title":"Neuropsychopharmacology"},{"key":"6860_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/164_2017_79","volume":"248","author":"RZ Litten","year":"2018","unstructured":"Litten RZ et al (2018) Advances in pharmacotherapy development: human clinical studies. Handb Exp Pharmacol 248:579\u2013613","journal-title":"Handb Exp Pharmacol"},{"key":"6860_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.nlm.2013.06.017","volume":"105","author":"Y-X Luo","year":"2013","unstructured":"Luo Y-X et al (2013) Role of amygdala in drug memory. Neurobiol Learn Mem 105:159\u2013173","journal-title":"Neurobiol Learn Mem"},{"issue":"2","key":"6860_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29020473","volume":"29","author":"N Martinez Naya","year":"2024","unstructured":"Martinez Naya N et al (2024) An overview of cannabidiol as a multifunctional drug: pharmacokinetics and cellular effects. Molecules 29(2):473","journal-title":"Molecules"},{"issue":"5","key":"6860_CR38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/mrm.22361","volume":"63","author":"S Moeller","year":"2010","unstructured":"Moeller S et al (2010) Multiband multislice GE-EPI at 7 tesla, with 16-fold acceleration using partial parallel imaging with application to high spatial and temporal whole-brain fMRI. Magn Reson Med 63(5):1144\u20131153","journal-title":"Magn Reson Med"},{"issue":"4","key":"6860_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pha0000272","volume":"27","author":"CN Nona","year":"2019","unstructured":"Nona CN, Hendershot CS, Le Foll B (2019) Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research. Exp Clin Psychopharmacol 27(4):359\u2013369","journal-title":"Exp Clin Psychopharmacol"},{"key":"6860_CR40","doi-asserted-by":"publisher","first-page":"1 S","DOI":"10.1016\/j.addbeh.2022.107360","volume":"132","author":"V Paulus","year":"2022","unstructured":"Paulus V et al (2022) Cannabidiol in the context of substance use disorder treatment: a systematic review. Addict Behav 132:1 S","journal-title":"Addict Behav"},{"issue":"2","key":"6860_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.neuroimage.2007.11.048","volume":"40","author":"RA Poldrack","year":"2008","unstructured":"Poldrack RA et al (2008) Guidelines for reporting an fMRI study. Neuroimage 40(2):409\u2013414","journal-title":"Neuroimage"},{"key":"6860_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173376","volume":"216","author":"E Rizkallah","year":"2022","unstructured":"Rizkallah E et al (2022) Cannabidiol effects on cognition in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. Pharmacol Biochem Behav 216:173376","journal-title":"Pharmacol Biochem Behav"},{"key":"6860_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1749-6632.2003.tb07089.x","volume":"985","author":"RE See","year":"2003","unstructured":"See RE et al (2003) Drug addiction, relapse, and the amygdala. Ann N Y Acad Sci 985:294\u2013307","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"6860_CR44","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/mrm.23097","volume":"67","author":"K Setsompop","year":"2012","unstructured":"Setsompop K et al (2012) Blipped-controlled aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced g-factor penalty. Magn Reson Med 67(5):1210\u20131224","journal-title":"Magn Reson Med"},{"issue":"3","key":"6860_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","volume":"7","author":"DJ Sholler","year":"2020","unstructured":"Sholler DJ, Schoene L, Spindle TR (2020) Therapeutic efficacy of cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Curr Addict Rep 7(3):405\u2013412","journal-title":"Curr Addict Rep"},{"issue":"4","key":"6860_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","volume":"43","author":"J Turna","year":"2019","unstructured":"Turna J et al (2019) Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res 43(4):550\u2013563","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"6860_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/adb.12495","volume":"23","author":"A Viudez-Mart\u00ednez","year":"2018","unstructured":"Viudez-Mart\u00ednez A et al (2018) Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 23(1):154\u2013164","journal-title":"Addict Biol"},{"key":"6860_CR48","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1369-1600.2011.00352.x","volume":"17","author":"S Vollstadt-Klein","year":"2012","unstructured":"Vollstadt-Klein S, Loeber S, Richter A, Kirsch M, Bach P, von der Goltz C, Hermann D, Mann K, Kiefer F (2012) Validating incentive salience with functional magnetic resonance imaging: association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients. Addict Biol 17:807\u2013816","journal-title":"Addict Biol"},{"issue":"6","key":"6860_CR49","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","volume":"54","author":"D Watson","year":"1988","unstructured":"Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54(6):1063\u20131070","journal-title":"J Pers Soc Psychol"},{"issue":"1","key":"6860_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41386-018-0218-2","volume":"44","author":"F Weiss","year":"2019","unstructured":"Weiss F, Gonzalez-Cuevas G (2019) Unique treatment potential of cannabidiol for the prevention of relapse to drug use. Neuropsychopharmacology 44(1):229\u2013229","journal-title":"Neuropsychopharmacology"},{"key":"6860_CR51","unstructured":"WHO (2024) Global status report on alcohol and health and treatment of substance use disorder. Geneva:World Health Organization, 2024"},{"issue":"11","key":"6860_CR52","first-page":"1177","volume":"13","author":"L Wirz","year":"2018","unstructured":"Wirz L et al (2018) An endocannabinoid receptor polymorphism modulates affective processing under stress. Soc Cogn Affect Neurosci 13(11):1177\u20131189","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"4","key":"6860_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059672","volume":"12","author":"S Zimmermann","year":"2022","unstructured":"Zimmermann S et al (2022) ON-ICE trial: investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial. BMJ Open 12(4):e059672","journal-title":"BMJ Open"},{"issue":"6","key":"6860_CR54","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41380-024-02869-y","volume":"30","author":"S Zimmermann","year":"2024","unstructured":"Zimmermann S et al (2024) Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Mol Psychiatry 30(6):2612\u20132619. https:\/\/doi.org\/10.1038\/s41380-024-02869-y","journal-title":"Mol Psychiatry"},{"issue":"1 Suppl","key":"6860_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW et al (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82\u201388","journal-title":"J Psychopharmacol"},{"key":"6860_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW et al (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259","journal-title":"Front Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06860-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:02:46Z","timestamp":1773216166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06860-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["6860"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06860-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was preregistered (German clinical trials database: DRKS00029993, study protocol can be accessed via DRKS.de; date of registration: 2022\u201308-10). All experimental procedures were approved by the local ethics committee of the University of Heidelberg. The clinical trial was designed and conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki.The trial consisted of two on-site visits, which were scheduled on two consecutive days, as screening visit and assessment visit. In the screening visit, participants underwent an assessment of individual characteristics and informed consent was obtained. To ensure the anonymity of all participants, subjects were identified solely by means of their pseudonymized individual identification code during the study. Individuals who did not consent to circulate their pseudonymised data were not included into the study. The data obtained in the course of the study was treated in accordance to the EU General Data Protection Regulation (GDPR) and national regulatory requirements (e.g. Federal Data Protection Act).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent before enrollment in the study. They were informed about the purpose of the research, their right to withdraw at any time without consequences, and the measures taken to protect their confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participants were informed that anonymized data and results would be published in scientific journals and other academic platforms. They provided explicit consent for the publication of their data in an aggregated and de-identified manner.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors report no biomedical financial interests or potential conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}